2026-06-14T03:42:15Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/202352024-09-22T09:13:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Kardos, Peter author Worsley, Sally author Singh, Dave author Roman-Rodriguez, Miguel author Newby, David E author Mullerova, Hana 2024-07-09T09:13:00Z 2024-07-09T09:13:00Z 2016 Kardos P, Worsley S, Singh D, Roman-Rodriguez M, Newby DE, Mullerova H. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2885-2895. 10.2147/COPD.S118867 1178-2005 International Journal of Chronic Obstructive Pulmonary Disease http://hdl.handle.net/20.500.13003/17226 27932872 L613447237 2-s2.0-85000580117 http://hdl.handle.net/20.500.12105/20235 Long-acting muscarinic antagonist (LAMA) or long-acting beta2-agonist (LABA) bronchodilators and their combination are recommended for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Although the efficacy of LAMAs and LABAs has been well established through randomized controlled trials (RCTs), questions remain regarding their cardiovascular (CV) safety. Furthermore, while the safety of LAMA and LABA monotherapy has been extensively studied, data are lacking for LAMA/LABA combination therapy, and the majority of the studies that have reported on the CV safety of LAMA/LABA combination therapy were not specifically designed to assess this. Evaluation of CV safety for COPD treatments is important because many patients with COPD have underlying CV comorbidities. However, severe CV and other comorbidities are often exclusion criteria for RCTs, contributing to a lack in external validity and generalizability. Real-world observational studies are another important tool to evaluate the effectiveness and safety of COPD therapies in a broader population of patients and can improve upon the external validity limitations of RCTs. We examine what is already known regarding the CV and cerebrovascular safety of LAMA/LABA combination therapy from RCTs and real-world observational studies, and explore the advantages and limitations of data derived from each study type. We also describe an ongoing prospective, observational, comparative post-authorization safety study of a LAMA/LABA combination therapy (umeclidinium/vilanterol) and LAMA monotherapy (umeclidinium) versus tiotropium, with a focus on the relative merits of the study design. eng Cardiovascular Cerebrovascular Real-world observational study Safety Umeclidinium Vilanterol Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD research article